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It is now well recognised that cardiac events occur relatively commonly in patients with acute community-acquired
pneumonia. While these events are more frequent in patients with underlying risk factors—such as those with
underlying chronic cardiovascular and respiratory comorbidities, the elderly, and in nursing home residents—they
also occur in patients with no underlying risks other than severe pneumonia. Recent research elucidating the
underlying pathogenic mechanisms related to these cardiac events has indicated a probable role for platelet
activation, which is possibly exacerbated by pneumolysin in the case of pneumococcal infections. This, in turn, has
resulted in the identification of possible therapeutic strategies targeting platelet activation, as well as the cardio-toxic
activity of pneumolysin. These issues represent the primary focus of the current review.
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For a considerable period of time, investigators have
been reporting on the occurrence of cardiac events in
patients with acute respiratory tract infections, including
community-acquired pneumonia (CAP) [1, 2]. Among
these cardiac events are acute coronary syndromes
(acute myocardial infarction [AMI]), acute or worsening
cardiac arrhythmias and new or worsening congestive
heart failure (CHF) [2]. The features of the association
between acute coronary events and arrhythmias and
CAP appear to fulfill the criteria for causality—namely,
that pneumonia is a cause of these events; whereas, in
the case of CHF, it appears the cause–effect relationship
may be bidirectional [2]. More recent studies are begin-
ning to give insight into the magnitude of this problem,
also indicating that these events tend to be particularly
common early on during the course of CAP, and also* Correspondence: charles.feldman@wits.ac.za
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factors, including older age, nursing home residence,
pre-existing cardiovascular disease, and in more severe
pneumonia [2]. Nevertheless, it is important to recognise
that in up to 50 % of cases with CAP in which acute car-
diac complications occur, there has been no prior history
of overt chronic cardiac disease [3].
It is interesting to reflect on the fact that in patients
with CAP, 50 % of the mortality within the first month is
due to comorbidities and not directly due to the conse-
quences of CAP (e.g. respiratory failure or sepsis), and
that cardiovascular diseases are also among the main
causes of death following a CAP episode [4, 5]. Further-
more, cardiovascular events (CVEs) are recognised to be
the primary causes of clinical failure in patients with
CAP and should be actively looked for in patients not
responding to standard medical care [6]. Importantly, it
is now recognised that acute cardiac events occurring
during the course of CAP are associated with negative
impacts on both short-term and long-term outcomes [2, 6].
This article will review the clinical studies of cardiac events
in patients with CAP, describe the likely pathogenic mecha-
nisms involved in this interaction, and discuss possiblele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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events, particularly in pneumococcal CAP.
Clinical studies
Acute infections and the onset of acute coronary
syndromes
In 1984, Spodick and colleagues [7] prospectively investi-
gated 150 patients hospitalised with AMI and an equiva-
lent number of age-, sex- and date-of-admission-matched
controls. They noted that there was an increased risk
(odds ratio [OR] 2.2; p < 0.02) of the occurrence of minor
acute respiratory symptoms in the patients with AMI
compared with the controls, and suggested that further in-
vestigations should be undertaken to determine if there
was a pathogenic relationship between acute respiratory
symptoms, considered likely to be of viral origin, and the
onset of AMI. Over many subsequent years, the asso-
ciation between acute infections, most commonly re-
spiratory infections, but also Staphylococcus aureus
bacteraemia, urinary tract infections and gastroenter-
itis, and the occurrence of acute coronary syndromes
has been documented [1].
CAP and acute cardiac events
Seedat and colleagues [8] undertook one of the first
studies investigating acute cardiac events in hospitalised
patients with acute CAP. The authors prospectively
studied consecutive patients with CAP who had no prior
or underlying cardiorespiratory illnesses. In addition to
recording demographic, clinical, microbiological, labora-
tory, and outcome data, they also performed electrocar-
diographic (ECG) and echocardiographic investigations
and measured serum enzyme, including cardiac enzyme
levels (creatinine kinase [CK], CK-MB fraction, and lac-
tate dehydrogenase [LDH]). A number of ECG changes
were documented, which returned to normal after a
mean of 2 days in survivors. The so-called S1, Q3, T3
pattern on ECG was associated with CK-MB leak, hyp-
oxia and a high Simplified Acute Physiology Score
(SAPS). The presence of P pulmonale, right axis devi-
ation and clockwise rotation correlated with hypoxia and
high SAPS score. Clockwise rotation also correlated with
raised serum LDH and CK-MB levels and high pulmon-
ary artery pressures. The overall patient mortality was
10.8 % and a number of negative prognostic factors were
documented. While there was no association between
the ECG changes and mortality, raised LDH, CK and
CK-MB levels correlated, among other factors, with need
for intensive care unit (ICU) admission and mortality.
Ramirez and colleagues [9] undertook a retrospective
observational study of 500 consecutive cases with CAP
enrolled into the Community-Acquired Pneumonia
Organization (CAPO) study. On hospital admission,
AMI was documented in 29/500 (5.8 %) patients,including 13/86 (15 %) patients with severe CAP, and
AMI was subsequently documented during hospitalisa-
tion in 13/65 (20 %) patients who experienced clinical
failure. Significant associations between AMI and Pneu-
monia Severity Index (PSI) (p = 0.05) and clinical failure
(p = 0.04) were noted after risk adjustment. The authors
concluded that in patients with CAP experiencing clinical
failure, AMI should be considered as a possible aetiology.
Other investigators have confirmed that acute cardiac
events [10] and both cardiovascular and cerebrovascular
events [11] are common and are associated with signifi-
cant morbidity and mortality in patients with CAP.
Perry et al. [12] examined a cohort of 50,119 subjects
extracted from databases of the Department of Veterans
Affairs (VA) from the period October 2001 to September
2007. The patients, of whom 98 % were males, had a
mean age of 77.5 years (standard deviation 6.7 years),
and the 90-day incidence of CVEs was 1.5 % for AMI,
10.2 % for CHF, 9.5 % for arrhythmia, 0.8 % for unstable
angina, and 0.2 % for stroke, with most events occurring
during hospitalisation. The authors suggested that CVEs
may play a significant role in CAP patient mortality and
that research was needed to determine whether appropri-
ate interventions could reduce the number of these CVEs.
Corrales-Medina et al. [13] studied 1,343 inpatients
and 944 outpatients with CAP for 30 days after their
presentation. They noted cardiac events (defined as new
or worsening CHF, new or worsening arrhythmia, or
AMI) in 358 (26.7 %) of inpatients and 20 (2.1 %) of out-
patients. More than half of these events were documented
in the first 24 h, and the factors that were particularly as-
sociated with their diagnosis included older age, nursing
home residence, pre-existing cardiovascular conditions
and indicators of pneumonia severity. These authors also
considered that further studies on risk stratification of
CAP patients for these complications and strategies for
their prevention and treatment need to be undertaken.
Risk stratification for acute cardiac events/cardiac
complications in patients with CAP
Viasus and colleagues [3] undertook a study to investi-
gate risk stratification for these acute cardiac events and
their prognosis. This was a prospective observational
study of a cohort of 3,921 hospitalised adults with CAP,
in whom a logistic regression analysis was performed to
document predictors for these acute cardiac events and
their mortality. Overall 315 (8 %) of these patients had ≥1
acute events during hospitalisation and multivariate
analysis documented a number of risk factors for these
events, which were used to develop a prognostication rule
that had an area under the receiver operating characteris-
tic curve of 0.73 (95 % confidence interval [CI] 0.70–0.76).
The case fatality rate was significantly higher in patients
who had an acute cardiac event (19.4 %) than in patients
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thors concluded that such a rule could be used to identify
CAP patients at high risk of cardiac complications.
Other investigators have sought to develop clinical
rules for risk stratification in patients hospitalised with
CAP [14]. In this study, 2 cohorts of patients were se-
lected, which represented the derivation and validation
cohorts. A point score system was developed from the
derivation cohort which, when applied to the validation
cohort, had good discrimination and outperformed the
PSI in predicting cardiac complications.
Aliberti and colleagues [15] studied the prevalence,
clinical characteristics, risk factors and impact on out-
come of AMI versus other CVEs in patients with CAP.
They documented that hospital mortality was higher in
patients with AMI in comparison to those who had
other CVEs and suggested that this should be consid-
ered when planning interventional studies.
Impact of prior therapy on risk of cardiac events in
patients with CAP
Using the Department of VA administrative database,
Soto-Gomez et al. [16] studied hospitalised CAP cases
≥65 years, in which the patients received antibiotics
within 48 h and had no prior diagnosis of a cardiac
arrhythmia. They documented that 3,919/32,689 (12 %)
patients developed cardiac arrhythmia within 90 days of
admission. Increased age, history of CHF, and need for
mechanical ventilation or vasopressors were significantly
associated with the occurrence of an arrhythmia and,
even after adjustment for confounders, incident cardiac
arrhythmias were associated with increased 30-day and
90-day mortality. However, beta-blocker use was associ-
ated with a decreased risk of arrhythmia (OR 0.92 [95 %
CI 0.85–0.99]). Other investigators documented that 376/
3,068 (12 %) hospitalised patients with CAP had a CVE
and, while hyperlipidaemia, more severe pneumonia and
S. aureus and Klebsiella pneumoniae pneumonias were as-
sociated with an increased risk, statin use was associated
with a decreased risk [17]. Both these investigators sug-
gested that studies of cardioprotective therapies in pa-
tients with CAP should be undertaken to determine if
they are able to attenuate cardiac risks [16, 17].
Long-term cardiovascular complications of CAP
More recently, a number of investigators have studied
long-term cardiovascular complications of CAP [18–21].
In one investigation adult patients with CAP initially
hospitalised in a tertiary hospital were followed up for
1 year, post-discharge [18]. Overall, 93/1,284 (7.2 %) pa-
tients died within 1 year of hospital discharge (68
[73.1 %] in the first 6 months). The main reasons for
mortality were infectious diseases, mainly pneumonia,
and acute CVEs. A number of risk factors were noted,including chronic obstructive pulmonary disease, dia-
betes, cancer, and dementia, which could help identify
cases at high risk of long-term mortality. Another study
documented cardiac complications (sometimes more
than one) in 55/310 (18 %) hospitalised CAP patients,
which included AMI or a new episode of atrial fibrilla-
tion in 32 and 30 patients, respectively [19]. However,
during the follow-up, 89 patients died (51 % of whom
had experienced an in-hospital cardiac complication, ver-
sus 26 % who had not; p < 0.001); in addition, 73 had a
CVE (47 % of patients who had experienced an in-
hospital cardiac event, versus 19 % who had not; p <
0.001). Among other factors, in-hospital cardiac events
were significantly associated with both overall mortality
and CVEs during follow-up. A third study in elderly
patients with CAP (≥65 years) [20] documented the
occurrence of new onset of heart failure in both the
intermediate and long-term (even after 5 years) follow-
ing hospitalisation, which had not been present on hos-
pital admission. These same authors confirmed in an
additional study [21] that hospitalisation for CAP is as-
sociated with both short-term and long-term risk of car-
diovascular disease and while the risk of cardiovascular
disease was greatest in the first year following hospital-
isation, it remained higher than in controls for up to
10 years of follow-up.
Currently, a study is being undertaken to document
whether various diverse inflammatory and immune
response mediators may be used as markers of both
short-term and long-term (1 year) occurrence of cardio-
vascular disease and mortality [22].
Non-cardiac complications in patients with AMI
Other investigators, in contrast, have studied patients
with AMI and looked for the occurrence of acute, life-
threatening and/or significant non-cardiac events that
were present on hospital admission of these patients
[23]. Such events occurred in approximately one-third of
patients with AMI. Of the 1,145 patients studied, pneu-
monia was noted in 7.2 % (n = 82), which were classified
as life-threatening in 1.5 % (n = 17) and significant in
5.7 % (n = 65). This study was undertaken early on in
2006 and, given what we have subsequently learned
about the occurrence of cardiac events in patients with
pneumonia, it would be interesting to speculate whether
the primary event in at least some of these cases with
AMI and severe pneumonia may have been the pneu-
monia itself.
Pneumococcal pneumonia and acute cardiac events
In 2007, Musher and colleagues [24] published the first
study investigating the possible association between
pneumococcal pneumonia and acute cardiac events.
This was a study undertaken over a 5-year period
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with pneumococcal pneumonia who developed AMI,
significant arrhythmia (namely atrial fibrillation or ven-
tricular tachycardia), or new onset or worsening of CHF.
Overall, 33/170 (19.4 %) patients had one or more of
these cardiac events: 12 had AMI (2 also had arrhythmia
and 5 had new or worsening CHF), 8 had an arrhythmia
(6 also had new onset CHF) and 13 had new or worsen-
ing CHF. There was a significantly higher mortality in
those patients with pneumococcal pneumonia who had
an acute cardiac event compared with those that did not
(p < 0.008).
Cardiac complication in patients with CAP: systematic
review and meta-analysis
Corrales-Medina et al. [25] undertook a systematic re-
view and meta-analysis to document the incidence of
major cardiac complications within 30 days in patients
diagnosed with CAP in order to determine the magni-
tude of the problem. Among the 17 articles (68 %) that
had reported on in-patient cohorts of CAP, data ex-
tracted from appropriate studies indicated that incidence
rate of overall cardiac complications was 17.7 %, heart
failure was 14.1 % (range 7–33 %), acute coronary syn-
dromes was 5.3 % (range 1–11 %) and cardiac arrhyth-
mias was 4.7 % (range 1-–11 %). Major conclusions
from this analysis were that cardiac complications were
common in patients with CAP and needed to be better
appreciated by physicians and patients alike, with early
recognition and appropriate management. Furthermore,
the investigators indicated the need for a better under-
standing of pathogenic mechanisms, of risk factors, and
of the impact of these cardiac events on patient out-
come. In addition, as indicated by these and other inves-
tigators, there needs to be a better understanding of
interventions to treat these complications (e.g. with the
use of cardioprotective medications), as well as to pre-
vent them (e.g. with use of influenza virus and pneumo-
coccal vaccination) [26]. Possible therapeutic and
preventative strategies, preceded by a brief overview of
current concepts in pathogenesis including the role of
pneumolysin in CAP-associated CVEs, are discussed in
more detail below.
Pathogenic mechanisms of CAP-associated CVEs
The role of platelets
Mirsaeidi et al. [27], recognising that platelets were in-
flammatory cells that played an important role in host
antimicrobial defences, undertook a study to evaluate
the association between abnormalities of the platelet
count and 30-day mortality in patients with CAP. These
investigators documented that the occurrence of either
thrombocytopaenia or thrombocytosis were associated
with in-hospital mortality in patients with CAP and thatthese abnormalities of the platelet count were better pre-
dictors of outcome than similar abnormalities of the
leukocyte count.
Recent and novel insights into the pathogenesis of
CAP-associated CVEs have been provided by the find-
ings reported in a study by Cangemi et al. [28]. This
study, which did not distinguish between viral and bac-
terial CAP, confirmed the high risk for development of
myocardial infarction, which peaked within 2 days of
hospitalisation. Notwithstanding disease severity and
heart ejection fraction, significant predictors of myocar-
dial infarction included elevated concentrations of the
circulating biomarkers of platelet activation, soluble
CD40 ligand, P-selectin (CD62P) and thromboxane B2
(a surrogate for thromboxane A2), as well as the mean
platelet volume [28]. The contention that platelet activa-
tion plays a pivotal role in orchestrating inflammatory
events which trigger, or more likely exacerbate, vascular
damage and dysfunction is supported by the steadily
increasing recognition of the critical role played by
these cells in mediating inflammatory and immune
responses [29–33].
Pro-inflammatory mechanisms by which platelet acti-
vation may contribute to the pathogenesis of bacterial
CAP in particular have recently been reviewed elsewhere
[30] and are briefly considered and updated here. The
most significant of these is activation and aggregation of
platelets by bacteria and their products such as cell-wall
components (lipoteichoic acids/peptidoglycans/endo-
toxins), DNA, and toxins such as pneumolysin and
staphylococcal α-haemolysin [34, 35]. These, in turn,
interact with and activate Toll-like receptors (TLRs) and
other types of pathogen-recognition receptors that are
expressed on platelets [29, 30, 36]. In this context, it is,
however, noteworthy that a role for platelet TLRs in
sepsis-mediated endothelial dysfunction has been chal-
lenged based on data derived from an experimental
model of Gram-negative sepsis [37].
Bacteria, specifically those belonging to the Staphylo-
coccus and Streptococcus genera, have also been reported
to mediate platelet activation by a complex and unusual
mechanism involving the interaction of these microor-
ganisms with platelet factor 4 (PF-4) present in platelet
α-granules [38]. The resultant complex binds to im-
munoglobulin G FcRIIA receptors, resulting in activa-
tion of the platelet pro-thrombotic, fibrinogen-binding
integrin, GPIIb/IIIa [38].
In addition to the aforementioned mechanisms, we
have recently observed that the major protein virulence
factor of the pneumococcus, pneumolysin, activates the
production of platelet-activating factor (PAF) by human
neutrophils in vitro. These effects, which were observed
at pathologically relevant concentrations of the toxin,
were dependent on its cholesterol-binding, pore-forming
Feldman and Anderson Pneumonia  (2016) 8:11 Page 5 of 10activity and unrelated to interaction with TLR4 [39]. In
this context, it is noteworthy that PAF has been reported
to contribute significantly to pneumolysin-induced lung
injury in a murine model of experimental infection [40].
We have also observed that pneumolysin, also at patho-
logically relevant concentrations, activates platelets
directly, according to upregulated surface expression of
the adhesion molecule CD62P, a constituent of platelet
α-granules. This pro-adhesive mechanism, which favours
the binding of platelets to both neutrophils and vascular
endothelium, was also dependent on the pore-forming
activity of pneumolysin [41].
These various mechanisms of platelet activation not
only favour homotypic aggregation resulting in the for-
mation of platelet clusters, but also heterotypic aggrega-
tion of these cells with neutrophils and vascular
endothelium. In this setting, activated platelets act as
bridges promoting neutrophil clusters, as well as binding
of neutrophils to vascular endothelium mediated by
CD62P and other pro-adhesive mechanisms [30, 32, 42].
If poorly controlled, systemic inflammatory mechanisms
involving platelets, neutrophils and vascular endothe-
lium predispose to endothelial damage and dysfunction,
promoting microvascular damage and coagulation [31].
Potential mechanisms of endothelial damage, resulting
in exposure of sub-endothelial collagen and von Willebrand
factor, include exposure to cytotoxic neutrophil-derived re-
active oxygen species and proteases. In addition, activated
platelets have been reported to induce the formation of
neutrophil extracellular traps (NETs) at sites of plaque rup-
ture in vivo [43]. NETs contribute to atherothrombosis by
several mechanisms. These include the cytotoxic actions of
their histone constituents on endothelium, as well as ex-
pression of functional, neutrophil-derived tissue factor [44].
Effects of pneumolysin
Pneumolysin is increasingly implicated in the pathogen-
esis of life-threatening acute cardiac complications in
CAP, albeit based on data derived from experimental
animal models. Brown et al. [45] have reported that ex-
perimental invasive pneumococcal disease (IPD) in mice
and rhesus macaques was associated with myocardial
damage and formation of cardiac microlesions. Trans-
location of the pneumococcus into the myocardium ap-
peared to be dependent on the pneumococcal adhesins,
choline-binding protein A and phosphorylcholine, while
microlesion formation was mediated by pneumolysin
[45]. Similar microlesions were detected in cardiac sec-
tions from patients with fatal IPD [45]. The authors con-
cluded “that the microlesions and the scarring that
occurs thereafter may explain why adverse cardiac
events occur during and following IPD” [45].
Essentially similar findings have been reported by
Alhamdi et al. [46]. The authors, who also used a murinemodel of IPD, observed that infection with pneumolysin-
expressing pneumococci, but not with strains deficient in
the toxin, resulted in significant elevations in circulating
cardiac troponins and myocardial injury [46]. These injuri-
ous effects on the myocardium were mimicked by intra-
venous administration of recombinant pneumolysin, but
not by a mutant toxin devoid of pore-forming activity, and
were attenuated by co-administration of pneumolysin-
sequestering liposomes [46]. Mechanistically, exposure of
murine cardiomyocytes to sublytic concentrations of the
toxin resulted in intense calcium influx and overload
followed by membrane depolarisation [46], as previously
reported for human neutrophils [47]. These disruptive ef-
fects of the toxin on cardiomyocytes were associated with
a “progressive reduction in intracellular calcium transient
amplitude, a key determinant of contractile force” [46].
Given its dual mechanism of mediation of cardiac
dysfunction—firstly, direct damage to cardiomyocytes;
and secondly, pro-inflammatory, pro-thrombotic ac-
tions involving activation of platelets and neutrophils
and damage to vascular endothelium—pneumolysin
appears to be a priority target in the prevention of
CAP-associated CVEs.
Treatment and/or prevention of CAP-associated
CVEs
Three potential strategies will be considered here: (i)
adjunctive anti-platelet pharmacological agents; (ii) strat-
egies targeting pneumolysin; and (iii) pneumococcal
immunisation.
Anti-platelet strategies
These have been covered extensively in recent reviews
[31, 48] and will be considered briefly here. Agents
which target platelet activation fall into several categor-
ies, targeting both mediators of activation and their
receptors, and include, but are not limited to, the
following:
 inhibitors of production of thromboxane A2
 antagonists of thromboxane A2 receptors
 antagonists of ADP-activated P2Y12 receptors
 antagonists of thrombin-activated proteinase-
activated receptor 1
 GPIIb/IIIa inhibitors.
Given the relatively recent appreciation of the role of
platelet activation in the pathogenesis of CAP-associated
CVEs, it is understandable that no compelling support-
ive data on the preventive potential of anti-platelet ther-
apies in this setting currently exists. However, of the
various categories of anti-thrombotic agents, aspirin,
which decreases the production of thromboxane A2 via
its inhibitory effects on cyclooxygenase-1, represents a
Feldman and Anderson Pneumonia  (2016) 8:11 Page 6 of 10relatively safe and inexpensive option in the setting of
prevention of CAP-associated CVEs.
In this context, it is noteworthy that the study alluded
to earlier by Cangemi et al. [28] describing the associ-
ation between CAP, platelet activation and CVEs, failed
to detect a protective effect of aspirin administered at a
daily dose of 100 mg on the occurrence of myocardial
infarction. The authors attributed the lack of benefit to
an inadequate dose of aspirin. In a subsequent prospect-
ive study in which a larger number (n = 1,005) of elderly
hospitalised patients with CAP was recruited, these same
authors investigated the effect of administration of as-
pirin (100 mg daily before and during hospital admis-
sion) on the 30-day mortality rate and overall incidence
of non-fatal CVEs [49]. During the follow-up period,
16.2 % of patients died: 19/390 (4.9 %) in the group of
aspirin-users and 144/615 (23.4 %; p < 0.001) in the
group of non-users, with a hazard ratio for total mortal-
ity of 2.07 (p = 0.029) [49]. Non-fatal CVEs occurred in
7 % of patients, 4.9 % and 8.3 % of whom were aspirin-
users and non-users, respectively (OR 1.77; p = 0.04).
Other studies, one focused on CAP [50], others on
acute lung injury (ALI)/acute respiratory distress syn-
drome (ARDS) [51–53] have reported significant benefit
of pre-hospitalisation administration of anti-platelet
therapies, including aspirin, on various outcomes such
as requirement for intensive care treatment, length of
hospital stay, incidence of ALI/ARDS, and mortality.
These findings were not, however, confirmed in a large
multicentre, international observational study (n = 3,855
patients) focused on the potential benefit of pre-
hospitalisation administration of aspirin on development
of ALI following hospital admission [54]. Although univar-
iate analysis revealed a reduced incidence of ALI in
patients receiving aspirin therapy (OR 0.65; p = 0.010), this
protective effect was attenuated using propensity score
analysis (OR 0.70; p = 0.072) [54]. Nonetheless, the
authors conceded that prospective intervention trials were
justified. In this context, a recently published study [55],
albeit involving a relatively small number of patients with
ARDS (n = 202) admitted to a single medical and surgical
ICU over an 18-month period, is noteworthy. The authors
observed that administration of aspirin pre-hospitalisation
and during ICU stay was associated with a significant
reduction in mortality (OR 0.38; p = 0.04) [55].
Although aspirin in particular, and possibly other anti-
platelet therapies show promise in the prevention of the
major cardiovascular and pulmonary complications of
CAP, there is a clear need for stringently controlled, de-
finitive intervention trials in this setting.
Strategies targeting pneumolysin
Given the well-recognised involvement of pneumolysin
in the pathogenesis of pneumococcal CAP and its majorpulmonary complications [40, 56, 57], together with in-
creasing evidence implicating the toxin in the aetiology
of CVEs associated with this condition, pneumolysin is
clearly a priority target for therapeutic intervention. Two
types of strategy exist: firstly, the use of agents, specific-
ally macrolide and macrolide-like antibiotics, which tar-
get production of pneumolysin by the pneumococcus;
and secondly, agents which attenuate the cytotoxic and
pro-inflammatory activities of the toxin, specifically sta-
tins and intravenous cholesterol-risk liposomes.
Macrolides
Unlike bactericidal antibiotics, such as beta-lactams,
which potentiate the release of pneumolysin [58], macro-
lides, via their predominantly bacteriostatic inhibitory ef-
fects on protein synthesis, potently suppress the production
of the toxin by the pneumococcus. These inhibitory effects
of macrolides on the production of pneumolysin, which are
evident at sub-inhibitory concentrations of these agents
[59, 60] even in the setting of macrolide resistance [61],
may underpin their utility as adjuncts to beta-lactams in
the treatment of severe pneumococcal disease [58, 62].
Statins
Statins, almost exclusively in the setting of pre-
hospitalisation administration, have been reported in a
number of studies to reduce CAP-related mortality and to
protect against the development of CAP [reviewed in 31].
In the case of pneumococcal CAP, statins, specifically sim-
vastatin, have been reported to attenuate the harmful ac-
tivities of pneumolysin. Apart from protecting isolated
human brain microvascular endothelial cells [63] and air-
way epithelial cells [64] against the cytotoxic actions of
pneumolysin, simvastatin has also been found to reduce
mortality in a murine sickle-cell disease model of
experimental pneumococcal infection [63]. While
these activities of simvastatin appear to be related to
interference with pneumolysin/membrane cholesterol
interactions, it is also noteworthy that statins possess
alternative anti-inflammatory activity unrelated to their
membrane cholesterol-lowering activities that target vari-
ous inflammatory cell types, including platelets [31].
However, as with conventional anti-platelet agents, the
potential of statins to target CVEs, as well as pulmonary
complications, in patients with recently diagnosed CAP
awaits the outcome of stringently controlled intervention
trials.
Cholesterol-enriched liposomes
Intravenous co-administration of penicillin together with
liposomes containing high concentrations of cholesterol
in particular, as well as sphingomyelin, within 10 h after
experimental infection of mice, has been found to pro-
tect against development of septicaemia and mortality in
Table 1 Potential therapeutic/preventative strategies targeting
cardiac events in patients with community-acquired pneumonia
• Anti-platelet agents
o inhibitors of production of thromboxane A2
o antagonists of thromboxane A2 receptors
o antagonists of ADP-activated P2Y12 receptors
o antagonists of thrombin-activated proteinase-activated receptor 1
o GPIIb/IIIa inhibitors





o PCV 13 with or without immunogenic pneumolysoid
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penicillin only [65]. The authors attributed the protective
effects of the liposomes to sequestration of pneumolysin.
Although innovative, the practicality of this approach in
the clinical setting is debatable.
Pneumococcal immunisation
The protective effect of immunisation in the prevention
of influenza-associated acute coronary events is well
recognised [66–68], suggesting that a similar relationship
may exist in the case of pneumococcal polysaccharide
vaccine 23 (PPV23), which has been available since 1983
[69]. In this context, it is noteworthy that a large case-
control study documented a significant decrease of >50 %
in the rate of myocardial infarction in recipients of PPV23,
which was evident from 2 years and onwards following
administration of the vaccine [70]. More recently, a
systematic review and meta-analysis of 11 cohort studies
covering the period 2000–2013, which included 332,267
participants, concluded that administration of PPV23 con-
ferred transient protection against both myocardial infarc-
tion and cerebrovascular events [71].
These apparently protective effects of PPV23 in the
prevention of CVEs have, however, been challenged by
the findings of a number of large case-control and
population-based cohort studies which failed to confirm
protection against AMI, ischaemic stroke, transient is-
chaemic events and all-cause mortality [66, 67, 72, 73].
In another population-based cohort study of adults pre-
senting with CAP, PPV23 immunisation was associated
with a 58 % reduction in acute coronary syndrome
events occurring within 90 days of pneumonia [73].
However, sensitivity analyses revealed that the protective
effect of PPV23 was most likely attributable to a con-
founding “healthy vaccinee” effect [74].
Issues which should be considered in future studies
designed to evaluate the potential of pneumococcal im-
munisation in protecting against the development of CVEs,
either in the general population or those with CAP include:
(i) the confounding potential of prior influenza immunisa-
tion, which may result in overestimation of the benefit of
pneumococcal immunisation [75]; and (ii) assessment of
the benefit of new generation pneumococcal vaccines, spe-
cifically pneumococcal conjugate vaccine 13 (PCV13) with
improved immunogenicity. While a recent study [76] has
documented significant protection against pneumococcal
infection in the elderly with the use of PCV13, there have
been no studies specifically addressing the impact of
PCV13 immunisation on CVEs. However, given the in-
creasing realisation of the probable involvement of pneu-
molysin in the pathogenesis of CVEs secondary to
pneumococcal CAP, the inclusion of an immunogenic
pneumolysoid with PCV13 (or a similar polysaccharide
conjugate vaccine) may offer maximal benefit [77].Potential therapeutic and preventative strategies are
shown in Table 1.Conclusion
The role of CAP in triggering often fatal acute coronary
syndromes, almost exclusively in hospitalised patients, is
clearly well recognised. The risk for development of car-
diac complications is highest soon after diagnosis with
about 90 % of these events detected within 7 days and
more than half within the first 24 h. Mortality attribut-
able to CAP-related cardiovascular abnormalities may be
associated with pre-existing plaque formation (AMI, pre-
dominantly silent) or to unrelated causes (arrhythmias),
the former being more common. The major risk factors
include older age, nursing home residence, severity of
CAP, chronic cardiovascular and respiratory comorbidi-
ties and smoking. Although most evident in the acute
phase of CAP, it is, however, noteworthy that the risk for
development of new-onset heart failure in elderly adults
previously hospitalised for CAP extends to 1 year, albeit
at a lower rate, remaining evident up to 10 years after
initial diagnosis. This includes patients who had previ-
ously experienced and survived intra-hospital CAP-
related cardiac complications. In this context, CVEs have
been reported to account for more than 30 % of deaths
at long-term follow-up averaging 1–5.4 years, possibly
due to CAP-related exacerbation, as well as possibly per-
sistence of the inflammatory mechanisms described
above. Promising therapeutic strategies include those
targeting platelet activation, especially aspirin. In the
case of pneumococcal CAP, macrolides, statins and
cholesterol-loaded liposomes interfere with the produc-
tion or bioactivity of pneumolysin, while new generation
vaccines offer the prospect of prevention.
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The authors searched PubMed (Medline) and Google
using the following combinations of topics: CAP and/or
community-acquired pneumonia and/or pneumonia
AND acute cardiac events and/or acute myocardial
infarction and/or arrhythmia and/or cardiac and/or car-
diac events and/or cardiac failure and/or cardiovascular
and/or cardiovascular events and/or congestive cardiac
failure and/or congestive heart failure and/or heart fail-
ure and/or neutrophils and/or neutrophil extracellular
traps and/or pneumococcus and/or pneumolysin and/or
platelets and/or platelet activating factor.
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